Tag: Targeted Therapy

Changing the Status Quo: Four Landmark Studies and their Implication for Melanoma Treatment

By Cody R. Barnett, MRA Director of Communications | 13 November 2017 In News, Science

The crown jewel of the Melanoma Research Alliance has always been—and will always be—good science. Through science, we not only gain a better understanding of melanoma, but the ability to translate that understanding into better treatments, which in turn lead to a better quality of life for people with melanoma. At MRA, solid scientific leadership is at the forefront of everything we do. That’s why the MRA Board of Directors was thrilled to hear a presentation by fellow Board member and world-class researcher, Dr. Suzanne Topalian, on four landmark studies and their implications for melanoma treatment.

Read More


Strides and Obstacles in Melanoma Research Spotlight on Martin McMahon, PhD

By Pamela Goldsmith, MRA Director of Communications | 6 June 2017 In Science, Treatment

Like so many in the melanoma research field, Martin McMahon, PhD, Huntsman Cancer Institute’s senior director of pre-clinical translation and Professor at the University of Utah, entered the melanoma field by accident.

Read More


The Genetics of Melanoma Goes Deep

By Kristen Mueller, Ph.D., MRA Scientific Program Director | 6 June 2017 In News, Science, Treatment

Due to the rapid advancements in DNA sequencing technologies, our understanding of the underlying genetic causes of cancer has increased substantially in the past decade. In the case of melanoma, researchers have now characterized in great detail the genetic changes that occur within tumor cells in melanoma of the skin, leading to the FDA approval of drugs targeting mutations in BRAF and MEK.

Read More


What Gut Bacteria Tell Us About Treating Melanoma and Other Cancers

By Pamela Goldsmith, MRA Director of Communications | 3 April 2017 In News, Science, Treatment

Despite success in the use of immunotherapy to treat cancer by harnessing the body’s immune system to fight it, a major difficulty continues to be the range of responses to treatment among patients. It’s why researchers are exploring why some cancer patients exhibit astounding results with little side effects while others receive no benefits to the treatment and/or experience severe side effects.

Read More


Melanoma Prevention: The Latest Advances & Future Directions

By Pamela Goldsmith, MRA Director of Communications | 28 February 2017 In Events, Policy, Prevention, Science

During my interview with Susan Swetter, MD, Professor of Dermatology,
Stanford University and VA Palo Alto, at the Melanoma Research Alliance Ninth Annual Scientific Retreat in Washington, DC, I inquired about the Panel Discussion she was part of titled: News from the field: What’s going well and what remains to be done?

Read More


Researcher Q&A: Dr. Vashisht Yennu Nanda

3 December 2015 In Science

MD Anderson\'s Dr. Yennu Nando explains his research for melanoma.

Read More


Melanoma and the Problem of Drug Resistance

8 October 2015 In Science

In 2002, researchers discovered a link between mutated BRAF genes and nearly half of all melanoma tumors. Since then, BRAF inhibitors—drugs that target mutated BRAF—have become a leading go-to weapon in the battle against melanoma. Their job is to cut off signals sent by altered BRAF that promote the rapid...

Read More


On the Path to Precision Medicine for Melanoma Patients

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 16 June 2015 In Science

There is no denying the transformative success of new treatments for melanoma ranging from molecularly targeted agents for BRAF-mutant melanoma to immunotherapies like anti-CTLA4 and anti-PD-1 drugs. Indeed, the treatment of BRAF-mutant melanoma is a prime example of Precision Medicine; that is, matching treatments to a patient’s specific disease.

Read More

Login

×